Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer
Status:
Active, not recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This research study is comparing the combination of drugs Crizotinib and Enzalutamide as a
possible treatment for metastatic castration-resistant prostate cancer (mCRPC).